Home Cart Sign in  
Chemical Structure| 263717-53-9 Chemical Structure| 263717-53-9

Structure of Propyl pyrazole triol
CAS No.: 263717-53-9

Chemical Structure| 263717-53-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%). PPT also exerts anti-diabetic effects in mouse models.

Synonyms: PPT

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Propyl pyrazole triol

CAS No. :263717-53-9
Formula : C24H22N2O3
M.W : 386.44
SMILES Code : C(C1C(C2C=CC(=CC=2)O)=NN(C2C=CC(=CC=2)O)C=1C1C=CC(=CC=1)O)CC
Synonyms :
PPT
MDL No. :MFCD03453628
InChI Key :IOTXSIGGFRQYKW-UHFFFAOYSA-N
Pubchem ID :5040063

Safety of Propyl pyrazole triol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HBE33 cells 1-100 nM 6 hours PPT increased Alt Ext-induced IL-33 release in hBE33 cells Allergy. 2021 Jan;76(1):255-268
HaCaT keratinocytes 10 nM 4 days To study the effects of ER-α and ER-β agonists on keratinocyte proliferation and differentiation. Results showed that the ER-β agonist (DPN) increased cell proliferation and keratin-19 expression while decreasing galectin-1 expression. Int J Mol Med. 2016 Jan;37(1):21-8
Endothelial progenitor cells (EPCs) 100 nM 4 hours PPT mimicked the stimulatory effects of estradiol on capillary formation via ER-α Hypertension. 2010 Sep;56(3):397-404
Human dermal fibroblasts 100 nM 48 hours To assess the individual effects of ERα and ERβ on FN expression, PPT significantly increased FN expression Arthritis Res Ther. 2013 Jan 10;15(1):R10
Normal human bronchial epithelial cells (NHBE) 1-100 nM 6 hours PPT increased Alt Ext and HDM-induced IL33 expression in NHBE cells Allergy. 2021 Jan;76(1):255-268
Primary cortical neurons 10 nM to 1 µM 6 hours to 48 hours To investigate the effect of E2 reducing Cav1.2 protein expression through estrogen receptor α (ERα) Aging Cell. 2019 Aug;18(4):e12961
MCF-7 human breast cancer cells 0.01 nM, 0.1 nM, 1 nM, 3 nM, 10 nM 7 days To evaluate the effects of PPT on MCF7 microtissues, including cell count and gene expression changes. PPT treatment increased nuclear counts in a dose-dependent manner with an EC50 of 0.3986 nM. Gene expression analysis showed significant upregulation of PDKZ1 under PPT treatment. Sci Rep. 2024 Feb 6;14(1):2999

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Ovariectomized APP/PS1 mice (Alzheimer's disease model) Subcutaneous injection 1 mg/kg Once daily for two weeks To investigate the effect of PPT reducing Cav1.2 protein and improving cognitive function through ERα Aging Cell. 2019 Aug;18(4):e12961
Sprague-Dawley rats Ovariectomized rats Subcutaneous injection 1 mg/kg Once daily for 7 days To study the effect of ER-β agonist (DPN) on wound healing. Results showed that the ER-β agonist (DPN) accelerated epidermal regeneration. Int J Mol Med. 2016 Jan;37(1):21-8
Female Long-Evans rats Ovariectomy model Subcutaneous injection 10 mg Single injection, tested 24 hours later To investigate the effect of PPT on effort-based decision making in female rats. PPT alone increased the choice of the high-reward lever, especially when 10 presses were required. This effect was further enhanced 24 hours post-injection. Neuropsychopharmacology. 2012 Jan;37(2):390-401
Rats Cocaine self-administration model Intra-NAc injection 10 nM Administered on day 29 and day 30 of withdrawal Intra-NAc injection of PPT on day 30 of withdrawal significantly decreased cue-induced cocaine seeking. J Neurosci. 2015 May 27;35(21):8042-58
Male C57Bl/6 mice Cardiac arrest and cardiopulmonary resuscitation model Intravenous injection and subcutaneous implantation 2 µg (intravenous) and 50 µg/day (subcutaneous implant) Single intravenous injection followed by continuous subcutaneous administration for 3 days To evaluate the effect of ER-α agonist PPT on neuronal survival after cardiac arrest. Results showed that PPT did not significantly reduce neuronal injury in the striatum or hippocampal CA1 region. J Cereb Blood Flow Metab. 2009 Feb;29(2):277-86
Mice Ovariectomized female mice Implanted slow-release pellet 2.5 mg 60 days To evaluate the effect of estrogen receptor alpha agonist on the formation of intracranial aneurysms, results showed that PPT (estrogen receptor alpha agonist) did not reduce the incidence of aneurysms in ovariectomized mice. Neurosurgery. 2014 Dec;75(6):690-5; discussion 695
Rats Hemorrhagic shock model Subcutaneous injection 5 μg/kg Single dose at the onset of resuscitation To evaluate the effect of PPT on the function of splenic CD4+ T lymphocytes and splenic injury after hemorrhagic shock, results showed that PPT restored the proliferation and cytokine production capacity of CD4+ T lymphocytes and alleviated splenic injury Sci Rep. 2021 Apr 5;11(1):7508
C57BL/6J mice Gonadectomy model Intraperitoneal injection 5.2 µg/25g mouse Single dose, measured after 24 hours To investigate the effect of ER alpha agonist on cardiac mitochondrial function in gonadectomized mice. Results showed that ER alpha agonist (PPT) did not modulate State-3 respiration in OVX female or ORX male mice. Front Endocrinol (Lausanne). 2023 Oct 17;14:1181044

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.59mL

0.52mL

0.26mL

12.94mL

2.59mL

1.29mL

25.88mL

5.18mL

2.59mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories